Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT04556435
Official study title

Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy

Study summary

The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung cancer patients and individuals without lung cancer ("healthy" controls). The breath sample analysis will help investigators describe and identify profiles of VOCs found in the breath of patients with lung cancer when compared to normal breath profiles using infrared spectroscopy. This work will help validate early proof of concept results conducted with prototype technology and later stage NSCLC breath samples, and inform future breath testing analysis.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 18, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Breathe BioMedical Inc

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Breathe BioMedical Inc
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • LC Group:
  • ≥ 18 years;
  • Able to give informed consent;
  • Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
  • Clinical evidence of lung cancer (metastatic or primary), inclusive of those receiving non-curative treatment, has not yet been treated or is not currently on treatment;
  • No history of or any other active cancer;
  • Able to provide a breath sample; Control Group:
  • ≥ 18 years;
  • Able to give informed consent;
  • Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);
  • No history of lung cancer or any other active cancer and is eligible for lung cancer screening;
  • Able to provide a breath sample;
Reasons someone may not be able to joinExclusion criteria
  • Has received or is currently receiving curative treatment and may no longer have lung cancer;
  • Cannot give informed consent;

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mia MartinezOrange, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 18, 2023. Always confirm current availability with the study team.

View original record ↗